Abi Siva MD
LightNews LightNews
abisivamd.bsky.social
Abi Siva MD
@abisivamd.bsky.social
32 followers 74 following 8 posts
Breast oncologist, Director of Medical Oncology #Hollings @MUSC, Fellowship Director #bcsm
Posts Replies Media Videos
Reposted by Abi Siva MD
oncodaily.bsky.social
ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care
@myesmo.bsky.social @ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMODailyReporter #BreastCancer #ADCs
ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care - OncoDaily
ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care / ADCs, Antibody drug conjugates, Breast Cancer, cancer, Dana-Farber Cancer
oncodaily.com
June 13, 2025 at 10:44 AM
Reposted by Abi Siva MD
oncodaily.bsky.social
Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

oncodaily.com/stories/cele...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer
Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More - OncoDaily
Linda Evangelista reveals her breast cancer journey, emphasizing early detection, resilience, and hope after diagnosis and treatment.
oncodaily.com
June 13, 2025 at 10:47 AM
Reposted by Abi Siva MD
oncodaily.bsky.social
Reflecting on Experiences After ASCO and AMA Meetings - Ashley Love Sumrall
@ashleysumrallmd.bsky.social @ascocancer.bsky.social

oncodaily.com/blog/asco-an...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO #AMA
Ashley Love Sumrall: Reflecting on Experiences After ASCO and AMA Meetings - OncoDaily
Ashley Love Sumrall: Reflecting on Experiences After ASCO and AMA Meetings / AMA, ASCO, Ashley Love Sumrall, cancer, OncoDaily, Oncology
oncodaily.com
June 13, 2025 at 10:50 AM
Reposted by Abi Siva MD
danafarber.bsky.social
Shail Maingi, MD, brought her experience in LGBTQ+ inclusive cancer care to India, supporting efforts to better serve LGBTQ+ patients.

Read how this global effort is supporting more inclusive care: bit.ly/4dBsI4M
Dana-Farber Oncologist Brings LGBTQ+-Centered Health Expertise Abroad
Published: May 19, 2025Updated: June 2, 2025Written by: Lukas Harnisch-WeidauerJyoti Bajpai, MD, DM, an oncologist practicing in the Apollo Hospital network in India, is well versed in treating rare cancers, but when she encountered someone with prostate cancer who was undergoing gender-affirming hormone replacement therapy, she found surprisingly little data to inform her approach.  The ... Read more
bit.ly
June 12, 2025 at 3:00 PM
Reposted by Abi Siva MD
erikahamilton9.bsky.social
Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer.

We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!

@oncbrothers.bsky.social
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...
Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breas...
www.astrazeneca.com
May 7, 2025 at 1:01 PM
Reposted by Abi Siva MD
drsgraff.bsky.social
Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged.

27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25

@oncoalert.bsky.social
May 30, 2025 at 8:12 PM
Reposted by Abi Siva MD
drsgraff.bsky.social
ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cr up oss over design. #ASCO25 @oncoalert.bsky.social
May 31, 2025 at 8:45 PM
Reposted by Abi Siva MD
dfcibreastonc.bsky.social
Check out the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (June 1st-6th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
June 9, 2025 at 4:10 PM
Reposted by Abi Siva MD
dfcibreastonc.bsky.social
Dr. Sara Tolaney @stolaney1.bsky.social shares key take-aways from #ASCO25. #BreastCancer #SERENA6 #MBC #MetasticBreastCancer Watch the video here:
touchoncology.com?p=138380&pos...
June 12, 2025 at 1:09 PM
Reposted by Abi Siva MD
dfcibreastonc.bsky.social
@dfcibreastonc.bsky.social is leading the ADEPT study, examining the non-chemotherapy combination of HER2-directed therapy (trastuzumab and pertuzumab) + hormonal therapy as a treatment after surgery for early HR+/HER2+ #BreastCancer. Call 877-338-7425 or visit:
www.dana-farber.org/clinical-tri...
June 12, 2025 at 1:13 PM
abisivamd.bsky.social
One of my most favorite slides form #ASCO25 from the CHALLENGE Trial showing exercise can match or beat drug effects. Powerful data
June 13, 2025 at 3:00 AM
abisivamd.bsky.social
x.com/abisivamd/st...
Abi Siva MD on X: "ER+/HER2-bca relapsing on adjuvant abemaciclib - @DFCI15/163 (9.2%) pts recurred after adjuvant abema, Median durations: 8.0 mo (abema), 18.5 mo (ET), 3.0 mo (1Lmtx). In 12 w/ paired bx, 50% lost ER; 90% of 10 had p53 alterations at recurrence. No RB1 loss https://t.co/j6t1cLpyJh" / X
ER+/HER2-bca relapsing on adjuvant abemaciclib - @DFCI15/163 (9.2%) pts recurred after adjuvant abema, Median durations: 8.0 mo (abema), 18.5 mo (ET), 3.0 mo (1Lmtx). In 12 w/ paired bx, 50% lost ER; 90% of 10 had p53 alterations at recurrence. No RB1 loss https://t.co/j6t1cLpyJh
x.com
June 13, 2025 at 2:54 AM
Reposted by Abi Siva MD
mattwynia.bsky.social
Thoughtful, provocative (in the best way) and helpful essay on why and how to talk with patients about racial disparities and excess risk attributable to racism. www.nejm.org/doi/full/10....
Acknowledging Racism, Building Trust — Conversations That Matter in Maternal Medicine | NEJM
Recognizing their increased risks during pregnancy and frustrated by the slow pace of change, an Ob/Gyn decides to discuss racism and risks with Black and Indigenous patients at their first visit.
www.nejm.org
June 11, 2025 at 11:20 PM
Reposted by Abi Siva MD
mattwynia.bsky.social
New interns start in 20 days. At some hospitals 100% of residents are IMGs. These mostly serve the most needy areas, and these systems are going to collapse if the travel ban, with no exceptions for physicians, stays in place. www.medpagetoday.com/meetingcover...
AMA to Advocate for IMGs in Visa Limbo Due to Trump Policies
Delayed appointments for J-1 visas is a 'healthcare delivery emergency,' one delegate said
www.medpagetoday.com
June 13, 2025 at 2:00 AM
abisivamd.bsky.social
Another highly anticipated readout: Trodelvy + Keytruda shows statistically significant & clinically meaningful PFS improvement in 1L PD-L1+ mTNBC! Big news for frontline treatment

www.gilead.com/news/news-de...
Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD L1 Metastatic Triple Negativ...
Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD L1 Metastatic Triple Negativ...
www.gilead.com
April 21, 2025 at 7:05 PM
abisivamd.bsky.social
Happy to be part of the #ASCOAdvocacysummit Day2 - training session- powerful training from oncology leaders and legislators committed to advancing cancer policy. Grateful for the insights, momentum, and shared mission to improve care for all patients.
April 7, 2025 at 5:27 PM
abisivamd.bsky.social
Great to be #ASCOAdvocacysummit reception today, surrounded by passionate advocates united in the mission to improve cancer care. Nearly 180 advocates from across the country have come together to drive change. Proud to represent SC @MUSC. @ishwaria.bsky.social @drsgraff.bsky.social
April 7, 2025 at 12:52 AM
abisivamd.bsky.social
Only a few hours left to submit your abstract to #ESMOBreast! A lot is happening in the world, but let’s keep pushing forward with research and innovation. Just submitted mine—good luck to everyone submitting! 💪 #bcsm
February 11, 2025 at 4:41 PM
Reposted by Abi Siva MD
jama.com
Viewpoint: The Trustworthy and Responsible AI Network (TRAIN), established by multiple health systems and
@microsoft.com, aims to advance the safe, effective, and equitable use of #AI in health care.

ja.ma/3WUsQ89

#MedSky
Figure. TRAIN’s Relationship to Other Entities in the Evolving Health Artificial Intelligence (AI) Ecosystem
February 10, 2025 at 5:31 PM
Reposted by Abi Siva MD
drsgraff.bsky.social
Congratulations all!! @stolaney1.bsky.social @lymphomadoc.bsky.social @ryannipp.bsky.social and more! #FASCO
ascocancer.bsky.social American Society of Clinical Oncology @ascocancer.bsky.social · Feb 6
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.

Learn More: brnw.ch/21wQwer
February 7, 2025 at 10:42 AM
Reposted by Abi Siva MD
drgattimays.bsky.social
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
February 3, 2025 at 11:48 AM
Reposted by Abi Siva MD
tmprowell.bsky.social
#MedSky
You can contact your elected officials in Congress even if you don’t know who they are. Call the Congressional switchboard (📸 below), & they will connect to the right Rep/Senators based on your address. You can also find them online here: www.congress.gov/members/find...
January 28, 2025 at 10:31 PM
Reposted by Abi Siva MD
drgattimays.bsky.social
Join us 2/1/25 at the Hilton Columbus at Easton @osucccjames.bsky.social Update from the #SABCS24 👋Experts from #TheJames @mskcancercenter.bsky.social #Emory will address the latest insights and practical guidance presented at #SABCS24. Register here 👉 ccme.osu.edu/continuing-m...
January 5, 2025 at 2:08 PM
Reposted by Abi Siva MD
jameabraham.bsky.social
www.gene.com/media/press-... @oncoalert.bsky.social
Genentech: Press Releases | Monday, Jan 27, 2025
Discover the latest news about our company, our products, our policies, and our people.
www.gene.com
January 28, 2025 at 10:59 AM
abisivamd.bsky.social
Sharing our recent meta-analysis on the utility of cryotherapy in preventing peripheral neuropathy among #breastcancer patients. #oncsky #bcsm
pubmed.ncbi.nlm.nih.gov/39827229/
Sensory PN: RR = 0.19 [0.05–0.66], p = 0.009
Motor PN: RR = 0.18 [0.03–0.99], p = 0.0491
A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel - PubMed
The use of cryotherapy decreased the occurrence of CTCAE grade ≥ 2 PN by 55%. Cold intolerance was the most frequently reported adverse effect associated with cryotherapy, but this adverse effect did ...
pubmed.ncbi.nlm.nih.gov
January 22, 2025 at 3:57 AM